General Information of Drug Off-Target (DOT) (ID: OTFU678I)

DOT Name V-type proton ATPase subunit e 2 (ATP6V0E2)
Synonyms V-ATPase subunit e 2; Lysosomal 9 kDa H(+)-transporting ATPase V0 subunit e2; Vacuolar proton pump subunit e 2
Gene Name ATP6V0E2
UniProt ID
VA0E2_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Pfam ID
PF05493
Sequence
MTAHSFALPVIIFTTFWGLVGIAGPWFVPKGPNRGVIITMLVATAVCCYLFWLIAILAQL
NPLFGPQLKNETIWYVRFLWE
Function
Subunit of the V0 complex of vacuolar(H+)-ATPase (V-ATPase), a multisubunit enzyme composed of a peripheral complex (V1) that hydrolyzes ATP and a membrane integral complex (V0) that translocates protons. V-ATPase is responsible for acidifying and maintaining the pH of intracellular compartments and in some cell types, is targeted to the plasma membrane, where it is responsible for acidifying the extracellular environment.
Tissue Specificity
Isoform 1 is expressed at high levels in heart, brain and kidney and also detected in inner ear epithelium, vestibule, testis, epididymis and bladder. Isoform 2 is expressed in heart, kidney, placenta and pancreas. Isoform 2 is not detected in frontal cortex, but is prevalent in all other brain areas.
KEGG Pathway
Oxidative phosphorylation (hsa00190 )
Metabolic pathways (hsa01100 )
Phagosome (hsa04145 )
Sy.ptic vesicle cycle (hsa04721 )
Collecting duct acid secretion (hsa04966 )
Vibrio cholerae infection (hsa05110 )
Epithelial cell sig.ling in Helicobacter pylori infection (hsa05120 )
Human papillomavirus infection (hsa05165 )
Rheumatoid arthritis (hsa05323 )
Reactome Pathway
Insulin receptor recycling (R-HSA-77387 )
Transferrin endocytosis and recycling (R-HSA-917977 )
Amino acids regulate mTORC1 (R-HSA-9639288 )
Ion channel transport (R-HSA-983712 )
ROS and RNS production in phagocytes (R-HSA-1222556 )
BioCyc Pathway
MetaCyc:HS15951-MONOMER

Molecular Interaction Atlas (MIA) of This DOT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
2 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate increases the methylation of V-type proton ATPase subunit e 2 (ATP6V0E2). [1]
Bisphenol A DM2ZLD7 Investigative Bisphenol A decreases the methylation of V-type proton ATPase subunit e 2 (ATP6V0E2). [10]
------------------------------------------------------------------------------------
9 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Ciclosporin DMAZJFX Approved Ciclosporin decreases the expression of V-type proton ATPase subunit e 2 (ATP6V0E2). [2]
Acetaminophen DMUIE76 Approved Acetaminophen decreases the expression of V-type proton ATPase subunit e 2 (ATP6V0E2). [3]
Doxorubicin DMVP5YE Approved Doxorubicin decreases the expression of V-type proton ATPase subunit e 2 (ATP6V0E2). [4]
Cupric Sulfate DMP0NFQ Approved Cupric Sulfate decreases the expression of V-type proton ATPase subunit e 2 (ATP6V0E2). [5]
Cisplatin DMRHGI9 Approved Cisplatin increases the expression of V-type proton ATPase subunit e 2 (ATP6V0E2). [6]
Azathioprine DMMZSXQ Approved Azathioprine decreases the expression of V-type proton ATPase subunit e 2 (ATP6V0E2). [7]
Urethane DM7NSI0 Phase 4 Urethane decreases the expression of V-type proton ATPase subunit e 2 (ATP6V0E2). [8]
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene decreases the expression of V-type proton ATPase subunit e 2 (ATP6V0E2). [9]
GALLICACID DM6Y3A0 Investigative GALLICACID decreases the expression of V-type proton ATPase subunit e 2 (ATP6V0E2). [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Drug(s)

References

1 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
2 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
3 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
4 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
5 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
6 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
7 A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
8 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
9 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
10 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
11 Gene expression profile analysis of gallic acid-induced cell death process. Sci Rep. 2021 Aug 18;11(1):16743. doi: 10.1038/s41598-021-96174-1.